BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 12053928)

  • 1. Fusidic acid cream for impetigo. Emergence of resistance to fusidic acid limits its use.
    Weston VC; Boswell TC; Finch RG; Perkins W
    BMJ; 2002 Jun; 324(7350):1394. PubMed ID: 12053928
    [No Abstract]   [Full Text] [Related]  

  • 2. Fusidic acid cream for impetigo. Findings cannot be extrapolated.
    Owen SE; Cheesbrough JS
    BMJ; 2002 Jun; 324(7350):1394. PubMed ID: 12053931
    [No Abstract]   [Full Text] [Related]  

  • 3. Fusidic acid cream for impetigo. Problem may be clinically important.
    Stoddart B; Collyns T; Denton M
    BMJ; 2002 Jun; 324(7350):1394. PubMed ID: 12053929
    [No Abstract]   [Full Text] [Related]  

  • 4. Fusidic acid cream for impetigo. Resistance trends must be monitored.
    Zadik P; Young N
    BMJ; 2002 Jun; 324(7350):1394. PubMed ID: 12053930
    [No Abstract]   [Full Text] [Related]  

  • 5. Fusidic acid cream for impetigo. Judicious use is advisable.
    Sule O; Brown N; Brown DF; Burrows N
    BMJ; 2002 Jun; 324(7350):1394. PubMed ID: 12053927
    [No Abstract]   [Full Text] [Related]  

  • 6. Fusidic acid cream for impetigo. Fusidic acid should be used with restraint.
    Brown EM; Wise R
    BMJ; 2002 Jun; 324(7350):1394. PubMed ID: 12052817
    [No Abstract]   [Full Text] [Related]  

  • 7. [Impetigo bullosa].
    Tveten Y
    Tidsskr Nor Laegeforen; 2003 Nov; 123(21):3089; author reply 3089. PubMed ID: 14618190
    [No Abstract]   [Full Text] [Related]  

  • 8. Fusidic acid-resistant Staphylococcus aureus in impetigo contagiosa and secondarily infected atopic dermatitis.
    Alsterholm M; Flytström I; Bergbrant IM; Faergemann J
    Acta Derm Venereol; 2010; 90(1):52-7. PubMed ID: 20107726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fusidic acid resistant Staphylococcus aureus and skin disease.
    Lomholt HB
    Acta Derm Venereol; 2010; 90(1):4. PubMed ID: 20107716
    [No Abstract]   [Full Text] [Related]  

  • 10. Impetigo in a population over 8.5 years: incidence, fusidic acid resistance and molecular characteristics.
    Rørtveit S; Skutlaberg DH; Langeland N; Rortveit G
    J Antimicrob Chemother; 2011 Jun; 66(6):1360-4. PubMed ID: 21393202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of antibacterials of Staphylococcus aureus isolated from impetigo patients.
    Nishijima S; Nakagawa M
    J Int Med Res; 1997; 25(4):210-3. PubMed ID: 9283995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presence of the epidemic European fusidic acid-resistant impetigo clone (EEFIC) of Staphylococcus aureus in France.
    Laurent F; Tristan A; Croze M; Bes M; Meugnier H; Lina G; Vandenesch F; Etienne J
    J Antimicrob Chemother; 2009 Feb; 63(2):420-1; author reply 421. PubMed ID: 18978362
    [No Abstract]   [Full Text] [Related]  

  • 13. [An epidemic of bullous impetigo in the municipality of Austevoll in the year 2002].
    Rørtveit S; Rørtveit G
    Tidsskr Nor Laegeforen; 2003 Sep; 123(18):2557-60. PubMed ID: 14714041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial.
    Koning S; van Suijlekom-Smit LW; Nouwen JL; Verduin CM; Bernsen RM; Oranje AP; Thomas S; van der Wouden JC
    BMJ; 2002 Jan; 324(7331):203-6. PubMed ID: 11809642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonal spread among Swedish children of a Staphylococcus aureus strain resistant to fusidic acid.
    Osterlund A; Eden T; Olsson-Liljequist B; Haeggman S; Kahlmeter G;
    Scand J Infect Dis; 2002; 34(10):729-34. PubMed ID: 12477322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current options for the treatment of impetigo in children.
    Sladden MJ; Johnston GA
    Expert Opin Pharmacother; 2005 Oct; 6(13):2245-56. PubMed ID: 16218885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do Antimicrobial Resistance Patterns Matter? An Algorithm for the Treatment of Patients With Impetigo.
    Schachner LA; Andriessen A; Benjamin LT; Claro C; Eichenfield LF; Esposito SM; Keller L; Kircik L; Kwong PC; McCuaig C
    J Drugs Dermatol; 2021 Feb; 20(2):134-142. PubMed ID: 33538559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The decline of the impetigo epidemic caused by the epidemic European fusidic acid-resistant impetigo clone: an 11.5-year population-based incidence study from a community in Western Norway.
    Rørtveit S; Skutlaberg DH; Langeland N; Rortveit G
    Scand J Infect Dis; 2014 Dec; 46(12):832-7. PubMed ID: 25229166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial susceptibility of Staphylococcus aureus isolated from children with impetigo in China from 2003 to 2007 shows community-associated methicillin-resistant Staphylococcus aureus to be uncommon and heterogeneous.
    Liu Y; Kong F; Zhang X; Brown M; Ma L; Yang Y
    Br J Dermatol; 2009 Dec; 161(6):1347-50. PubMed ID: 19754868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fusidic acid in dermatology: an updated review.
    Schöfer H; Simonsen L
    Eur J Dermatol; 2010; 20(1):6-15. PubMed ID: 20007058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.